Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the cli...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open forum infectious diseases Ročník 9; číslo 10; s. ofac485
Hlavní autoři: Strezova, Ana, Diez-Domingo, Javier, Al Shawafi, Kamal, Tinoco, Juan Carlos, Shi, Meng, Pirrotta, Paola, Mwakingwe-Omari, Agnes, Adams, Michael, Ahonen, Anitta, Andrews, Charles, Athan, Eugene, BarbaGómez, Jose-Fernando, Barbanti, Piero, Barberan, Elisabeth, Baty, Alain, Bengtsson, Niklas, Berger-Roscher, Juergen, Blom, Katarina Berndtsson, Beytout, Jean, Boucher, Loïc, Boutry, Céline, Boye, Alain, Brault, François, Breger, Laurie, Cuixart, Carles Brotons, Caso, Covadonga, Cerna, Christine, Cheng, Huey-Shinn, Cheong, Hee Jin, Choo, Eun Ju, Cunha, Clóvis, Cunningham, Anthony L, Curiac, Dan, Daguzan, Benoit, Dahmen, Antje, Datta, Susan, Desole, Maria Giuseppina, Paolo, Emmanuel Di, Dionne, Marc, Dite, Petr, Dutz, Jan, Earl, John, Eckermann, Tamara, Ellison, William, Eremenko, Jurij, Esen, Meral, Eto, Takashi, Fabré, Xavier Farrés, Farrington, Cecil, Ferguson, Murdo, Ferrand, Pierre André, Finneran, Matthew, Francyk, David, Freedman, Marshall, Freeman, George, Freire, Antônio Tarcísio, Gal, Peter, Gauthier, Jean-Sebastien, Gerlach, Beatrice, Ghesquiere, Wayne, Gorfinkel, Iris, Grigat, Christine, Grosskopf, Josef, Hamann, Monika, Hanrion, Pascal, Hartley, Paul, Hastie, Andrew, Heaton, Ken, Himpel-Boenninghoff, Agnes, Horacek, Thomas, Hui, David Shu Cheong, Huong, Yieng, Hwang, Shinn-Jang, Icardi, Giancarlo, Illies, Gabriele, Irimajiri, Junya, Jacob, Wilson, Jambrecina, Alen, Avelino-Silva, Thiago Junqueira, Kalema, George, Kim, Hyo Youl, Klein, Christiane, Kleinecke, Uwe, Koenig, Hans-Joachim, Kokko, Satu, Kosina, Pavel, Koski, Susanna, Koskinen, Pekka, Kropp, Maximilian, Kuroki, Rie, Laajalahti, Outi, Lachance, Pierre, Lee, Jacob, Lee, Jin-Soo, Levins, Peter, Lipetz, Robert, Liu, Bo, Liu, Chiu-Shong, Lundvall, Martin, Magimaiseelan, Luci
Médium: Journal Article
Jazyk:angličtina
Vydáno: US Oxford University Press 01.10.2022
Témata:
Brief Report
ISSN:2328-8957, 2328-8957
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Potential conflicts of interest.  K.A.S. is a Modis employee, working on behalf of the GSK group of companies. A.M.O., M.S., A.S., and P.P. are employees of the GSK group of companies. P.P. and A.S. hold shares/stocks in the GSK group of companies as part of their employee remuneration. J.D.D. reports grants from the GSK group of companies, Sanofi, and MSD; consulting fees from Sanofi Pasteur and MSD paid to him and his institution; honoraria from the GSK group of companies and SEQIRUS (to him and his institution), outside the submitted work. J.C.T. reports grant/research support from the GSK group of companies. The authors have no other financial or nonfinancial interests to declare. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Study group members listed in the Acknowledgments
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofac485